Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria by Alexander M Upfill-Brown et al.
Upfill-Brown et al. BMCMedicine 2014, 12:92
http://www.biomedcentral.com/1741-7015/12/92
RESEARCH ARTICLE Open Access
Predictive spatial risk model of poliovirus to aid
prioritization and hasten eradication in Nigeria
Alexander M Upfill-Brown1*, Hil M Lyons1, Muhammad A Pate2, Faisal Shuaib3,4,5, Shahzad Baig4,6,
Hao Hu1, Philip A Eckhoff1 and Guillaume Chabot-Couture1
Abstract
Background: One of the challenges facing the Global Polio Eradication Initiative is efficiently directing limited
resources, such as specially trained personnel, community outreach activities, and satellite vaccinator tracking, to the
most at-risk areas to maximize the impact of interventions. A validated predictive model of wild poliovirus circulation
would greatly inform prioritization efforts by accurately forecasting areas at greatest risk, thus enabling the greatest
effect of program interventions.
Methods: Using Nigerian acute flaccid paralysis surveillance data from 2004-2013, we developed a spatial
hierarchical Poisson hurdle model fitted within a Bayesian framework to study historical polio caseload patterns and
forecast future circulation of type 1 and 3 wild poliovirus within districts in Nigeria. A Bayesian temporal smoothing
model was applied to address data sparsity underlying estimates of covariates at the district level.
Results: We find that calculated vaccine-derived population immunity is significantly negatively associated with the
probability and number of wild poliovirus case(s) within a district. Recent case information is significantly positively
associated with probability of a case, but not the number of cases. We used lagged indicators and coefficients from
the fitted models to forecast reported cases in the subsequent six-month periods. Over the past three years, the
average predictive ability is 86 ± 2% and 85 ± 4% for wild poliovirus type 1 and 3, respectively. Interestingly, the
predictive accuracy of historical transmission patterns alone is equivalent (86 ± 2% and 84 ± 4% for type 1 and 3,
respectively). We calculate uncertainty in risk ranking to inform assessments of changes in rank between time periods.
Conclusions: The model developed in this study successfully predicts districts at risk for future wild poliovirus cases
in Nigeria. The highest predicted district risk was 12.8 WPV1 cases in 2006, while the lowest district risk was 0.001
WPV1 cases in 2013. Model results have been used to direct the allocation of many different interventions, including
political and religious advocacy visits. This modeling approach could be applied to other vaccine preventable diseases
for use in other control and elimination programs.
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Background
Since the commitment by the World Health Assem-
bly to eradicate poliovirus in 1988, the disease burden
has dramatically declined by more than 99% to 223
cases reported in 2012 [1,2]. Yet, in the face of grow-
ing financial and political investments, polio remains
endemic in Nigeria, Pakistan, and Afghanistan and has
been repeatedly exported to other previously polio-free
*Correspondence: aupfillbrown@intven.com
1Institute for Disease Modeling, Intellectual Ventures, 1555 132nd Ave NE,
Bellevue, USA
Full list of author information is available at the end of the article
countries—leading the 65th World Health Assembly to
declare polio eradication a “programmatic emergency for
global public health” in 2012 [3].
Though substantial, the resources of the Global Polio
Eradication Initiative (GPEI), including vaccines, specially
trained personnel, and social mobilization campaigns, are
limited and must be targeted to high-risk areas within
endemic countries in order to maximize impact [4].
The GPEI supports the surveillance and survey collec-
tion designed to monitor program performance in these
areas [5]. However, converting these data sources into
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Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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operationally useful and scientifically valid measures of
future risk can be challenging.
Furthermore, before 2010, wild poliovirus (WPV) epi-
demics affected large portions of northern Nigeria, and
80 to 90 different districts were reporting cases within a
six-month period. Thus, the need for prioritization was
low, as cases were scattered across the whole of north-
ern Nigeria and outbreak response was the focus of the
problem. The lull in reported WPV cases in 2010 coupled
with the small number of WPV “infected” districts scat-
tered across northern Nigeria in 2011 suggested that the
epidemic in Nigeria had become more focused; a much
smaller number of districts were contributing to WPV
transmission in Nigeria. Increased focus by the program
was needed to anticipate which high-risk districts were at
highest risk for future cases in order to prevent further
transmission. Programmatically, the need to identify the
districts at highest risk was intensified by a planned surge
in technical and administrative capacity, supported by the
World Health Organization (WHO).
Currently, one systematic method for risk assessment at
the district level has been described in the literature: the
WHO’s method of regional polio risk assessment, which
uses a weighted linear combination of available indica-
tors [6]. This approach is currently used by all WHO
regional offices for supplementary immunization activity
(SIA) campaign planning and outbreak risk assessment.
As Lowther and colleagues recognize [6], this approach
has limitations: these weights are based on expert opin-
ion, not statistical modeling, and its historical predictive
accuracy has yet to be demonstrated.
Previous work has demonstrated the accuracy of WPV
outbreak prediction using hierarchical statistical model-
ing in the African region at the country/province level
[7]. This model incorporated measures of connectedness
between areas and population immunity and demon-
strated good predictive accuracy. However, in endemic
areas, operations are carried out at the district administra-
tive level or below; at this spatial scale, underlying causal
factors, such as migration, are poorly measured.
To better support modeling of spatial heterogeneity
and correlation, recent work focusing on other infectious
diseases has increasingly applied Bayesian spatial mod-
eling methods [8]. These methods have been used to
map infection prevalence in unmeasured areas for malaria
[9,10], schistosomiasis [11-15], soil-transmitted helminths
[16-18], and filariasis [19].
Only recently in infectious disease research have these
methods been used to aid in forecasting disease preva-
lence or incidence in a future time period [20,21]. Though
spatial models of infectious disease describe reported case
counts, these models rarely apply zero-inflated Poisson
and Poisson hurdle models to adjust for excess zeros
[22]; however, these models, with and without a spatial
component, have been used to analyze other ecolog-
ical and public health processes [23-26]. Rarely have
zero-inflated models been used to forecast future case
counts.
We present a predictive spatial hierarchical Poisson hur-
dle model for serotype 1 and serotype 3 WPV (WPV1
and WPV3) transmission. This model is currently incor-
porated in district-level prioritization planning in Nigeria.
Using this modeling framework, we identify the most
important risk factors of the presence ofWPV and the his-
torical number of WPV cases, and also highlight areas in
which these indicators are weakly informative. Due to the
sparsity of the data underlying the estimates of district-
level covariates, we employ a two-part methodology in
which these estimates are smoothed using a temporal
hierarchical model prior to their use as inputs to the
spatial Poisson hurdle models. We examine this model’s
historical ability to forecast districts that will report one
or more WPV cases six months in the future.
Methods
Description of the data
The primary source of information used in this analysis
is the Nigerian Acute Flaccid Paralysis (AFP) surveillance
database (maintained by the Nigerian WHO). When a
childhood AFP case is reported, two stool samples are
collected and tested for poliovirus. Information regarding
age, onset date, parent-reported oral polio vaccine (OPV)
dose history, and clinical symptoms is collected as part of
the initial case investigation, before the laboratory polio
diagnosis is completed. AFP can be caused by viruses
other than WPV, though the distribution of these viruses
and other causes of AFP are not well understood [27]. AFP
cases without confirmed poliovirus in either stool sam-
ple, that is, non-polio AFP (NP-AFP), are considered to be
a random sample of the population [28-30]. The age dis-
tribution of NP-AFP cases is peaked between 18 and 24
months (Figure 1A).
District (Local Government Area) population estimates
were taken from the 2006 Nigerian National Census [31];
absent specific demographic data for each district, the
under-five population was estimated to be 20% of the total
population of each districta. Each district’s population
density was calculated by dividing its under-five popula-
tion by its area computed using the district polygon file
[32]. For reference, Figure 2 shows a map of Nigeria.
Individually reported dose histories, vaccine-specific
campaign exposures, a probability model for campaign
participation, and vaccine-specific OPV efficacies based
on AFP surveillance data [33] were used to calculate the
probability that an individual is protected against paralysis
from each WPV serotype (Additional file 1, Eq. S1) [34].
Individual campaign exposure was defined as the number
of SIA campaigns occurring between birth and the date of
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Figure 1 AFP age distributions and implied impact of vaccination interruptions. (A), Comparison of age distribution of WPV-AFP cases and
NP-AFP cases between Jan 2004 and June 2013. (B), Reduction in calculated NP-AFP immunity in period of no vaccination based on flat under-five
age distribution and NP-AFP under-five age distribution in (A).
paralysis onset, based on the historical SIA calendar in the
district.
Both polio AFP and NP-AFP cases were linked to
districts in Nigeria and binned into six-month periods:
December throughMay or June throughNovember. In the
following, the former period is referred to as the first half
of a year and the latter as the second half of a year; for
example, the first half of 2008 refers to the period from
December 2007 through May 2008.
District-level OPV-induced population immunity was
taken to be the mean calculated OPV-induced immu-
nity of all NP-AFP cases in children under five years-old
occurring in a district within a six-month period. District
zero-dose fraction was computed as the proportion of NP-
AFP cases for children 0 to 59 months old for which there
were reported zero OPV doses in a district within a given
six-month period.
Recent caseload is equal to the total number of
WPV1 or WPV3 cases in a district in the previous six
months. Recent neighboring caseload, also sero-specific,
is the total number of WPV1 or WPV3 cases in bor-
dering districts in the previous six months. We used
AFP and campaign data from June 2004 through May
2013.
Figure 2Map of Nigerian states. Color signifies geopolitical region.
Upfill-Brown et al. BMCMedicine 2014, 12:92 Page 4 of 14
http://www.biomedcentral.com/1741-7015/12/92
Statistical methods
As only a small number of NP-AFP cases occur within
a single district within six months, the empirical esti-
mates of OPV-induced immunity and zero-dose fraction
are highly variable from one time period to another: more
than 10% of zero-dose fractions in adjacent time peri-
ods decreased by more than 0.1 (see Figure 3C, D), an
unrealistic difference given the under-five demographics.
We adjusted these estimates using a hierarchical temporal
smoothing model (see Additional file 1, Eq. S2, S3, S4, S5).
Model estimates over time forMaiduguri district in Borno
are presented as an example. The posterior mean of the
smoothed calculated immunity and zero-dose fraction
estimates were then used as indicators in the statistical
models of WPV transmission.
WPV1 and WPV3 caseloads were modeled using a
Poisson hurdle model: a two-part model consisting of
a Bernoulli component that models the probability of
reporting one or more WPV cases and a truncated Pois-
son portion that models the number of WPV cases in
infected districts (districts reporting one or more WPV
cases; see Additional file 1, Eq. S8, S9, S10) [35,36]. For
each component, we included spatially and non-spatially
dependent random effects to account for unobserved spa-
tially correlated risk factors [37,38]. Together, these terms
enable both local and global borrowing of information,
respectively. A bivariate conditional autoregressive (CAR)
prior was used to model spatial random effects, and a
bivariate normal prior was used to model non-spatial ran-
dom effects, as we expect areas with greater rates of WPV
transmission to report larger case counts [26].
A Bayesian estimation approach was utilized, and
models were fit using WinBUGS 1.4.3 [39] and the
R2WinBUGS and CODA packages [40,41] in R [42]. Dif-
fuse priors and hyper-priors were used for the regression
coefficients and the random effect precisions. The con-
vergence of Markov chain Monte Carlo (MCMC) models
was checked through visual inspection of chains and the
Gelman-Rubin potential scale reduction factor [43,44].
The selected model was determined using an iterative
subtractive approach to arrive at the most parsimonious
model with the lowest deviance information criterion
(DIC), a well- described method for quantifying the qual-
ity of a fit [25,45] (see Additional file 1 for full model
details).
The accuracy of model predictions was estimated
using prospective sampling: predictions were compared
to future data excluded from the initial analysis [46].
The selected model was applied historically using data
smoothed over a specified time period; the historical
caseload in an upcoming window was predicted using the
model coefficients estimated using data from prior time
Figure 3 Impact of statistical smoothing model. (A), Map of district NP-AFP WPV1 vaccine-derived immunity, December 2012 through May
2013. Districts colored gray if no data NP-AFP cases reported in this interval. (B), Map of smoothed district WPV1 immunity estimates for the same
period. See Discussion for explanation of the relatively low calculated immunity in southern districts. (C, D), Raw versus smoothed indicators over
time in Maiduguri, Borno district for WPV1 immunity estimates (C) and zero-dose fraction (D). The shaded region represents the point-wise 95%
posterior credible interval (CI) of parameter mean estimates.
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periods and covariates from the most recent time periodb.
The predictive power of the model was assessed using
receiver operator characteristic (ROC) analysis using the
“pROC” package in R [47]. The empirical area under
the ROC curve (AUC) was used to quantify the accu-
racy of model predictions of infected districts (districts
reporting >1 WPV1 case) [48]. As a rule of thumb, an
AUC of 0.5 to 0.7 indicates marginal predictive power,
an AUC of 0.7 to 0.9 indicates moderate predictive
power, and an AUC above 0.9 indicates strong predictive
power [49].
Uncertainties in the predicted district caseloads and dis-
trict ranks were estimated using 1,000 samples from the
posterior distribution of parameters. District rank was
determined by ordering districts according to predicted
WPV1 risk with 1 being most at risk and 774 being least
at risk. As districts are prioritized based on rank above a
certain threshold, we used samples from the posterior dis-
tribution of district ranks to estimate the probability of a
district belonging to the N districts of highest rank.
Results
Influence of data smoothingmodel
Data smoothing resulted in substantial changes in the esti-
mated regression coefficients; the impact of the smooth-
ingmodel is highlighted in Figure 3. The smoothingmodel
shrinks extreme district estimates from the first half of
2013 towards the mean (Figure 3A, B). We find the calcu-
lated population immunity to be low in southern districts
(see Figure 2 for map of Nigeria); see Discussion for pos-
sible explanations of this phenomenon. The reduction of
rapid fluctuations in values over time is highlighted in
Figure 3C and D.
The smoothing effectively captures major trends in the
data while reducing the amount of variability between
adjacent time points: fewer than 1.5% of changes in the
smoothed calculated immunity between adjacent time
periods are greater than 0.1 (none are greater than 0.15),
compared to 49.7% of changes greater than 0.1 for the
empirically calculated immunity. Additionally, fewer than
3% of relative immunity decreases between adjacent time
periods were greater than 20% in the smoothed immu-
nity model, while 43% of immunity decreases were greater
than 20% for empirical population immunity estimates.
Factors associated with WPV1 transmission
Regression analysis identified key covariates significantly
associated with the presence and number of WPV cases
at the district level. Model coefficients and random effect
variance components for different models are presented
in Table 1. The population density was not significantly
associated with the presence or number of WPV1 AFP
cases in a district. Zero-dose fraction was negatively asso-
ciated with only the number of cases in a district in the
full model; however, because this association is an artifact
of collinearity with population immunity (r = −0.77),
we did not include it in the selected model (r = −0.63
for type 3 population immunity and zero-dose fraction).
Recent caseloads in a district and in its neighboring dis-
tricts were positively associated with the presence of cases
in a district but not with the number of cases. The esti-
mated OPV-induced population immunity is significantly
associated with both the presence and number of WPV1
cases within a district.
In models of WPV3 in Nigeria, only the OPV-based
population immunity was significantly associated with the
number of cases in a district in the selected model, while
population immunity and recent cases in neighboring dis-
tricts were associated with the presence of WPV3 cases in
a district (see Additional file 1: Table S2).
A null model without covariates is included in Table 1
as a reference; this model only makes use of popula-
tion and historical outcome information, through spatial
and non-spatial random effects. Interestingly, the random
effects variance estimates are only marginally higher in
this model than in the selected model, though the covari-
ance between spatial random effects in the Poisson and
binomial portions is significantly greater than zero. Fixed
effect covariates therefore account for a fairly small pro-
portion of the model variance captured by the random
effects alone in the null model. This suggests that the
time-varying covariates contain additional information
not captured by random effects alone.
The magnitudes of the district-level random effect esti-
mates from the selectedmodel (Table 1) give an indication
of where fixed effects alone repeatedly overestimate or
underestimate the presence (Figure 4A) or number of
cases (Figure 4B) as a result of factors not included in
the model that affect WPV1 transmission (see Additional
file 1: Figure S1 for similar results for the WPV3 model).
Indicators in the binomial portion of the model overesti-
mate the presence of cases in southern districts (possibly
due to low estimated OPV-induced population immunity,
see Figure 3B) and underestimate the presence of cases
in northern districts. Population immunity and popula-
tion covariates underestimate the number of cases most
substantially in districts within Kano and Jigawa states
(Figure 4B).
PredictingWPV1 circulation in districts in Nigeria
Model forecasts are generated by combining predictions
from both portions of the model. The spatial distribution
of projected risk is largely determined by the binomial
portion of the model (Figure 5). The predicted pres-
ence and number of cases (outputs of the binomial and
Poisson portions, respectively) are distributed differently
in space, with the latter clustered in and around Kano
state (Figure 5C) and the former highest in the northeast
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Table 1 Covariate estimates for models using data throughMay 2013
Component Variable Full Selected Null
Poisson Intercept -11.21 -11.51 -12.68
(-11.88, -10.51) (-11.83, -11.17) (-13.03, -12.37)
Population Immunity -2.50 -1.80





Sqrt Recent Cases -0.05
(-0.11, 0.02)
Sqrt Neighboring Recent Cases 0.02
(-0.02, 0.05)
Bernoulli Intercept -0.91 -1.11 -3.60
(-1.64, -0.16) (-1.42, -0.80) (-3.80, -3.43)
Population Immunity -4.86 -4.74





Sqrt Recent Cases 0.19 0.19
(0.07, 0.31) (0.07, 0.32)
Sqrt Neighboring Recent Cases 0.17 0.17
(0.10, 0.23) (0.10, 0.23)
DIC 9263.6 9266.8 10121.3
N 13932 13932 13932
Variance Bernoulli CARa 1.51 1.50 1.48
Components (1.06, 2.08) (1.04, 2.04) (1.08, 1.98)
Bernoulli Indb 0.10 0.10 0.09
(0.06, 0.17) (0.05, 0.18) (0.05, 0.15)
Poisson CARc 0.49 0.46 0.67
(0.24, 0.86) (0.22, 0.79) (0.39, 1.05)
Poisson Indd 0.14 0.13 0.15
(0.08, 0.23) (0.07, 0.22) (0.08, 0.23)
Covariance CARe 0.10 0.07 0.42
(-0.23, 0.46) (-0.23, 0.39) (0.12, 0.77)
Covariance Indf -0.01 -0.01 -0.01
(-0.05, 0.04) (-0.07, 0.04) (-0.06, 0.04)
95% credible intervals (CI) are presented in parentheses underneath corresponding parameter estimates.
aSpatial random effects in Bernoulli portion of the model.
bNon-spatial random effects in Bernoulli portion of the model.
cSpatial random effects in Poisson portion of the model.
dNon-spatial random effects in Poisson portion of the model.
eSpatial random effect covariance.
fNon-spatial random effect covariance.
(Borno and Yobe states), northwest (Zamfara state), and
north central (Federal Capital Territory and Nasarawa
state) regions (Figure 5B).
To assess the historical predictive power of the model
over time, we used the area under the ROC curve (AUC)
of a ranked list of districts as a summary statistic of
the model’s predictive accuracy (Figure 6A). Within every
prediction interval, we estimated both smoothed param-
eters and model coefficients using the data preceding
the interval (Table 2). Over time, the selected model
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Figure 4Magnitude of random effect estimates in the selectedWPV1model. Estimated with data through May 2013. Sum of posterior mean
of spatial and non-spatial random effects in the Bernoulli portion (A) and Poisson portion (B) of the hurdle model. The estimates are on the logit
and log scale, respectively. These figures indicate that the model’s covariates overestimate the risk in southern districts and underestimate the risk in
northern Nigeria historically.
has performed relatively well, with 11 of 14 AUC esti-
mates greater than 0.8 and a mean AUC of 0.86 (SE =
0.01) over the past three years. The predictive accuracy
was similar for the selected WPV3 model; the mean
AUC over the last three years was 0.85 (SE = 0.02)
(Figure 6C).
Interestingly, the selectedWPV1model did not perform
better on average than a null model, suggesting that an
aggregate measure of spatially smoothed historical risk is
equally adept at predicting future infected districts as a
model that considers population immunity, recent cases,
and recent cases in neighboring districts. The mean AUC
of the null WPV1 model over the last three years was
0.86 (SE = 0.01). Similarly, the predictive accuracy of the
null WPV3 model was comparable to that of the selected
WPV3model; the mean AUC over the last three years was
0.84 (SE = 0.02).
In 2009, both the selected and null WPV1 models were
very poorly predictive. This result is largely due to a flare-
up of WPV1 in southern Nigeria in 2009, in districts that
had not previously reported a case (see Additional File 1:
Figure S3E, F). The relatively poor predictive power of the
model in the first half of 2010 (AUC = 0.71) is associated
with an uncharacteristically small number of reported
WPV1 cases (two cases).
As such, a useful quantity for policy makers is the
expected proportion of cases contained within a set
of the highest risk districts (Figure 6B). Historically in
Nigeria, 85 to 90% of future cases have appeared in
the 200 highest risk districts, and 55% of future cases
Figure 5Model predictions from the selected model for June through November 2013. (A), The predicted risk, or expected number of cases,
under the model. (B), The predicted probability of one or more reported cases, i.e., the output from the binomial portion of the hurdle model. (C),
The predicted number of reported AFP cases given an introduction (one reported AFP case). All estimates based on covariates from December 2012
through May 2013.
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Figure 6 Forecasting accuracy of historical WPV1 andWPV3models. (A, C), Area under the ROC curve for historical models by prediction
interval for WPV1 (A) and WPV3 (C). The null model contains only random effects. The selected models include population and estimated
population immunity in the Poisson portion and population immunity and recent caseload information in the binomial portion (Table 1 and
Additional File 1: Table S2). (B, D), Case sensitivity curves for selected WPV1 (B) and WPV3 (D)model predictions. The color signifies the prediction
interval. The number of cases in the given prediction interval is written to the right of the legend.
have appeared in the 100 highest risk districts under the
selected model.
Uncertainty in prioritization according to predicted
caseload
The model uncertainty can be translated into a district
rank uncertainty using 1,000 samples from the poste-
rior distribution of parameters (Figure 7A). The highest
and lowest ranked districts exhibit the lowest rank uncer-
tainty. Given a desired list size, the probability of a district
being included in the highest risk list can be calculated
(Figure 7B, C). Under the selected model, each of the 30
districts with highest predicted risk has more than a 90%
probability of being included in the 100 highest ranked
districts in June through November 2013.
Discussion
The smoothing model handles missing data and smooths
over unrealistic changes in indicators, such as rapid six-
month fluctuations in the under-five immunity estimated
from sparse NP-AFP samples. In the absence of any vacci-
nation, the under-five OPV-induced population immunity
should decrease by roughly 8-9% in a six-month period
(see Figure 1B)c. Though thresholds based on this or
similar considerations are not explicit in our smoothing
model, the smoothed variations between time periods are
more realistic than those in empirical data. Smoothing
models could be improved by limiting changes between
time points to demographically constrained values.
Despite its limitations [50], the OPV-based popula-
tion immunity, calculated using efficacies derived from
case-control population studies [29,33], is strongly asso-
ciated with the presence and case count of WPV1 at the
district level inNigeria. It is the only covariate significantly
associated with the number of cases in a district.
It is expected that the recent caseload is significantly
associated only with the expected presence of WPV1, as
recent circulation has a mixed effect on the future case
count. While a large number of cases within a time period
suggests potentially higher transmission (temporally and
spatially) from a large infectious reservoir, WPV1 circula-
tion will also boost natural immunity in an area, providing
additional protection and reducing the expected caseload
in the ensuing time period [50]. Indeed, we find that both
recent caseload within a district and in surrounding dis-
tricts are significantly associated with the probability of a
WPV1 case, but not the number of WPV1 cases.
Although increased population density is thought to
increase poliovirus transmission potential [51], we find no
association in either portion of the model. Due to data
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Table 2 Coefficient estimates from the selectedmodel applied historically
Component Variable 2012 2011 2010 2009 2008
Poisson Intercept -11.42 -11.50 -11.60 -11.80 -12.20
(-11.76, -11.09) (-11.87, -11.17) (-11.96, -11.24) (-12.22, -11.39) (-12.79, -11.69)
Population -1.95 -1.80 -1.60 -1.62 -1.28
Immunity (-2.40, -1.51) (-2.30, -1.31) (-2.09, -1.10) (-2.14, -1.11) (-1.92, -0.61)
Binomial Intercept -0.81 -0.54 -0.75 -1.43 -1.89
(-1.14, -0.46) (-0.91, -0.17) (-1.16, -0.35) (-1.81, -1.02) (-2.42, -1.36)
Population -5.24 -5.69 -5.03 -3.42 -3.17
Immunity (-5.82, -4.65) (-6.34, -5.07) (-5.71, -4.36) (-4.18, -2.71) (-4.19, -2.20)
Sqrt Recent 0.19 0.18 0.18 0.13 0.18
Cases (0.06, 0.32) (0.05, 0.30) (0.05, 0.31) (0.01, 0.26) (0.04, 0.33)
Sqrt Neighboring 0.17 0.18 0.16 0.06 0.02
Recent Cases (0.10, 0.24) (0.11, 0.25) (0.09, 0.23) (-0.01, 0.13) (-0.07, 0.10)
DIC 8732.4 8306.9 8107.3 7798.5 6200.7
N 12384 10836 9288 7740 6192
Variance Bernoulli CARa 1.47 1.49 1.41 1.59 1.81
Components (1.03, 2.03) (1.02, 2.06) (0.97, 1.98) (1.08, 2.23) (1.26, 2.52)
Bernoulli Indb 0.11 0.11 0.11 0.11 0.12
(0.06, 0.19) (0.06, 0.19) (0.06, 0.19) (0.06, 0.19) (0.06, 0.22)
Poisson CARc 0.47 0.49 0.50 0.51 0.61
(0.22, 0.80) (0.24, 0.85) (0.24, 0.86) (0.25, 0.85) (0.30, 1.02)
Poisson Indd 0.14 0.14 0.14 0.14 0.18
(0.07, 0.22) (0.07, 0.24) (0.08, 0.23) (0.08, 0.23) (0.10, 0.28)
Covariance CARe 0.04 0.04 0.06 0.26 0.36
(-0.28, 0.34) (-0.31, 0.41) (-0.28, 0.38) (-0.10, 0.63) (-0.06, 0.76)
Covariance Indf -0.01 -0.01 -0.01 -0.02 -0.03
(-0.07, 0.04) (-0.07, 0.04) (-0.07, 0.04) (-0.07, 0.04) (-0.10, 0.04)
Models are estimated using data through the first half of the year that identifies the model. 95% credible intervals (CI) are presented in parentheses underneath
corresponding parameter estimates.
aSpatial random effects in Bernoulli portion of the model.
bNon-spatial random effects in Bernoulli portion of the model.
cSpatial random effects in Poisson portion of the model.
dNon-spatial random effects in Poisson portion of the model.
eSpatial random effect covariance.
fNon-spatial random effect covariance.
limitations, population density was calculated at the dis-
trict level, which may be a poor representation of the
experienced population density on more functional scales
of transmission, such as the population density immedi-
ately surrounding the household reporting aWPV case. A
more fine-grained analysis is needed to better understand
the impact of population density of WPV transmission.
The ability to detect an association between zero-dose
fraction, an indicator of possible clustering of vulnera-
bility within a district, and the presence and number of
WPV1 cases was compromised by a strong correlation
between population immunity and zero-dose fraction.
The collinearity between these indicators resulted in a
negative association between zero-dose fraction and the
number of WPV1 cases in a district, while in a model
without population immunity, zero-dose fraction has a
strong positive association with the number of cases in a
district.
Although the historical predictive accuracy is high,
covariates in the selected model do not substantially
improve the forecasting ability of the model over the
null model. In a null model, the random effects cap-
ture the mean historical frequency and number of WPV1
cases within a district. This result suggests that although
dynamic indicators are associated with WPV1 trans-
mission, historical transmission patterns are stronger
predictors of future transmission than available model
covariates.
The decrease in performance in 2009 is caused by a
flare-up in WPV1 cases in southern districts with no
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Figure 7Model uncertainty in relative district risk ranking. Prediction interval from 6/2013 through 11/2013. 1,000 posterior samples of model
parameters were used to generate 1,000 risk scores and 1,000 ranks for each district. (A), Distribution of posterior district ranks by district. Probability
of district rank being in the top 100 (B) and in the top 200 (C). Estimates ordered by district rank at posterior mean of parameters.
history of WPV1 transmission in our dataset; because
the spatial random effects alone are strong predictors of
future caseloads, this modeling approach places very lit-
tle risk in areas with no historical cases in the dataset.
The selected model performed as poorly as the null model
during this time period, indicating that factors other than
calculated OPV-derived population immunity and local
transmission contributed to this outbreak.
The outputs from the predictive models are well suited
for use in prioritization by public health organizations. In
Nigeria, model forecasts are used to inform sub-national
SIA planning and allocation of specialized personnel. Pri-
oritization analysis played a critical role in the distribution
of technical and administrative field staff—supported by
both WHO and the Nigerian government—to the high-
est risk Local Government Areas across the north during
the capacity surge in June 2012. WHO alone grew an
initial staff of 744 to over 2,900, an increase of nearly
300%. In addition to supporting SIA planning, moni-
toring, and evaluation, these personnel have supported
household-based micro planning, intensified AFP surveil-
lance activities, and helped strengthen routine immuniza-
tion activities. Outreach from the federal government to
state governors and district chairmen to increase local
political buy-in was also heavily increased around this
time; prioritizations based on the predictive risk model
results were also used to direct this surge in advocacy.
These efforts can be partly credited for the absence of
cases in 2013 from the northwest of Nigeria, the area
of focus for political engagement in the latter half of
2012. F Since June 2013, model outputs have been com-
bined with results and input from the National Primary
Health Care Development Agency (NPHCDA), Centers
for Disease Control and Prevention (CDC), and WHO to
categorize a subset of districts as “high risk” and “high-
est risk”. This categorization has been used to direct a
number of interventions across partner organizations in
Nigeria. Management support teams, comprising high
level personnel from NPHCDA and other GPEI partner
agencies, are deployed to prioritized districts seven to ten
days before a SIA campaign to address challenges limit-
ing vaccination coverage. Prioritized districts are selected
for advocacy visits targeted at local political, traditional,
and religious leaders. Additionally, supplemental logis-
tics funds are provided to prioritized districts to enhance
the ability of teams to vaccinate hard-to-reach and scat-
tered settlements. The tracking of vaccinators using GPS-
enabled smart phones has been targeted to prioritized
districts. Often, these districts receive the first implemen-
tation of an intervention planned to eventually deploy
across northern Nigeria.
Outside of national program planning, district prior-
itization categorizations are closely monitored by state
governors and district chairmen. Because of additional
support, a prioritized district reporting aWPV case is held
more accountable than a non-prioritized district.
The quantification of uncertainty in risk rank can also be
a useful tool for policy makers. As changes in prioritiza-
tion are an additional strain on resources (due to required
reallocation of people and materials), the quantification of
uncertainty in rank can enable objective decisions regard-
ing changes to the prioritization of an area. If a district is
newly ranked in the top 100 or 200 highest risk areas, pol-
icy makers may only want to prioritize if there is a high
level of certainty that the district belongs in the highest
risk group.
One aspect not considered in the model was the
migration and transport structures connecting non-
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neighboring districts. With data to inform such struc-
tures, we may be better able to predict infection in naive
southern districts.WPV1 case information was only avail-
able beginning in 2004 for this study. More historical data,
with instances of transmission in these areas, could also
have improved the forecasting accuracy of the model dur-
ing these time periods. Seasonal variations and trends,
such as those used in predictive models for meningitis in
France and Mali [20,21], could be incorporated, though
the six-month time scale of model predictions required
due to data sparsity may be too large for this technique to
be useful.
Additional covariates or more representative data are
needed to more fully understand WPV transmission in
Nigeria. In the selected model, a substantial amount of
residual spatial variation remains, as is demonstrated
in Figure 4. This variation may be due to other fac-
tors such as poverty, malnutrition, sanitation, and level
of health services, which influence WPV transmission
potential and population vaccine efficacy [52,53]. In addi-
tion, the inclusion of a number of operational factors
could greatly improve the model. Indicators capturing
district management performance, training quality, vacci-
nator selection, population accessibility (the presence of
hard-to-reach areas within districts, which may be sea-
sonal), and non-compliance are currently missing from
the model. Such indicators are an important part of reg-
ular program operations. Furthermore, these indicators
could be more dynamic than current smoothed indica-
tors, thus improving the responsiveness of model outputs
to short-term changes in performance.
Based on the magnitude of district-level random effects,
we find that in large portions of northern Nigeria covari-
ates underestimate the probability of the presence of
WPV1 in a district, while in southern Nigeria, these
covariates overestimate the probability of WPV1 pres-
ence. The latter could occur partly because we assume
that vaccine efficacy is the same throughout the coun-
try, which results in relatively low population immunity
estimates in southern districts (Figure 3). This observa-
tion is a direct result of the differential number of SIA
campaigns executed in northern and southern Nigeria
historically: over the last few years, more than twice as
many campaigns have been carried out in northern states
than in southern states. There is evidence and theory to
suggest that vaccine efficacy is not uniform across Nigeria;
it may actually be higher in southern Nigeria [33,54], pos-
sibly due to a lower burden of non-polio enteroviruses,
which are known to interfere with OPV efficacy [55,56].
OPV-derived population immunity estimates based on
geographically sensitive vaccine efficacies could resolve
this anomaly and strengthen the measured associa-
tion between calculated population immunity and WPV
transmission.
There are several possible sources of statistical bias in
our analysis. Though we treated NP-AFP as a random
sample of the population in an area, NP-AFP may be
under-representative of subpopulations in a district, espe-
cially higher risk sub-populations in areas with worse
sanitation and less access to health services. This NP-
AFP bias is also likely to vary by location. Though the
annual rate of NP-AFP (8/100,000 under fifteen) is higher
than the minimum WHO guideline (2/100,000 under fif-
teen), small sample sizes limit the temporal and spatial
resolution of this analysis.
Another limitation of this analysis is the recall bias that
arises from the oral history collected from the mothers of
reported AFP cases. It is possible that they may over- or
under-report the number of OPV doses received by the
child. It is also possible that the literacy level of the care-
givers may influence the accuracy of reported doses. Our
analysis does not make allowances for the impact of inse-
curity on the observed AFP detection rates in some states,
such as Borno, Yobe and Kano; the effects may be more
meaningful in data collected since December 2012.
There likely exist important heterogeneities in WPV
transmission and associated factors below the district
level: SIA activities are often planned and carried out at
the subdistrict (ward) level in Nigeria. The mean popu-
lation immunity may be poorly representative of at-risk
populations, which will attenuate estimated relationships
in the model. Certain populations, such as nomadic peo-
ples [57], may be missed by routine AFP surveillance; in
this case, there may be additionalWPV cases not included
in the analysis. Poorly performing wards may persist in
districts with low average risk, as each ward has a focal
person responsible for vaccinator selection and training.
The population diversity within a district, which often
include both rural and urban environments, suggests that
the ward level is a more representative level for anal-
ysis, although we are severely constrained by a lack of
historical data and sparse sample sizes at the subdistrict
level.
Conclusion
The model developed in this study successfully predicts
districts at risk for future wild poliovirus cases in Nigeria.
Furthermore, the smoothing model handles missing data
and smooths over unrealistic changes in important covari-
ates. By quantifying uncertainty in risk ranking, we min-
imize the likelihood that decision makers respond to
stochastic fluctuations in predicted risk over time. Pre-
dictive model outputs are well suited for use by public
health organizations: in Nigeria, model forecasts are used
to inform sub-national SIA planning and to direct diverse
interventions.
In order to more fully understandWPV transmission in
Nigeria, additional covariates or more representative data
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are necessary. Heterogeneity in indicators or outcomes
below the district level were not considered by this anal-
ysis due to data limitations, though there is evidence
that this may be important. In addition, better metrics of
connectedness between districts—informed by road net-
works or other transportation structures–could also have
improved our model.
In addition to its usefulness for polio eradication
through maximizing the impact of political and finan-
cial resources, this modeling approach could be extended
to other vaccine preventable diseases (VPDs), such as
measles. With adequate surveillance data, this type of
predictive model provides a principled way of prioritiz-
ing administrative areas in future control or elimination
efforts.
Endnotes
aThis is compatible with a relatively low life
expectancy, especially in northern Nigeria. The 2008
Demographic and Health Survey (DHS) in Nigeria
estimates an under-five proportion of 0.171 [58]. In this
analysis, the exact fraction is not particularly crucial; as a
single value is used for all districts, the relative
populations of the districts are preserved.
bFor example, to make predictions about the second
half of 2008 (June to November 2008), we smoothed
indicators through May 2008, and estimated a model
with data from July 2004 through May 2008. We then
used population immunity and caseload information
from the first half of 2008 (December 2007 through May
2008) to make predictions and rank districts according to
model outputs.
cWaning of individual immunity has been documented
[59,60]; however, this should not be relevant on a
six-month time scale.
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